U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07466238) titled 'HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer' on Feb. 19.
Brief Summary: Biliary tract cancer (BTC), including cholangiocarcinoma and gallbladder cancer (GBC), is a group of malignancies with highly heterogeneous, highly aggressiveness, and poor prognosis. Surgery is recognized as the only curative treatment for BTC, however, only about 20% BTC patients are eligible for curative resection since most patients with BTC are diagnosed at an advanced stage. The median overall survival (OS) in patients with unresectable BTC is typically less than 6 months. For patients with unresectable BTC, gemci...